Nisoldipine is a dihydropyridine calcium-channel blocker with potent vasodilatory effects and a favorable side-effect profile.
Answers are grounded in this paper and cite their sources.
Nisoldipine's profile supports consideration in vasodilatory regimens; leaves open need for contemporary head-to-head trials.
Nisoldipine is a new calcium-channel blocker of the dihydropyridine subclass, with a chemical structure similar to nifedipine. It has been used in clinical trials to assess its efficacy and safety in patients with hypertension, angina pectoris, and congestive heart failure. Similar to other dihydropyridines, nisoldipine is a potent peripheral and coronary dilator. The most optimal dosage regimen has not been established in clinical trials. The drug appears to have a favorable side-effect profile.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: